Compare Ascendis Pharma A/S (ASND) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs LyondellBasell Industries NV — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while LyondellBasell Industries NV trades at $58.46 (market cap $18.19B). The key difference: Ascendis Pharma A/S and LyondellBasell Industries NV are close in size by market cap, and LyondellBasell Industries NV pays a 7.31% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LYB | |
|---|---|---|
Market Cap | $17.74B | $18.19B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $82.38 |
52-Week Low | $163.32 | $42.28 |
Enterprise Value | $18.11B | $29.81B |
Dividend Yield | — | 7.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
LYB trades at $56.36, up 1.74% today, with a bearish technical signal and mixed earnings history including a recent Q1 2026 beat. The company shows declining revenue and negative net income margins, though it maintains positive operating cash flow and recently announced a partnership for recycled-content packaging with Mondelez. Analyst consensus is a Buy with a $73.11 price target, indicating potential upside from current levels.
Outlook remains cautious due to profitability challenges and elevated debt, but cost-cutting and strategic shifts toward higher-margin polymers offer recovery potential. Key risks include persistent margin pressure and macroeconomic sensitivity, while institutional sentiment is divided between growth optimism and fundamental concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
